Roivant Sciences Ltd Cash Flow Conversion Efficiency
Roivant Sciences Ltd cash flow conversion efficiency. Based on the latest financial reports, Roivant Sciences Ltd (ROIV) has a cash flow conversion efficiency ratio of -0.040x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-196.48 Million) by net assets ($4.97 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Roivant Sciences Ltd (2019–2025)
Cash flow conversion efficiency of Roivant Sciences Ltd from 2019 to 2025. This chart illustrates how Roivant Sciences Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Roivant Sciences Ltd (ROIV) share price today for real-time trading data and today's change.
Roivant Sciences Ltd Cash Flow Conversion Ratio Explained
Roivant Sciences Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Roivant Sciences Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Roivant Sciences Ltd ranked by their cash flow conversion efficiency. Also see market value of Roivant Sciences Ltd for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
NN Group NV
AS:NN
|
-0.057x |
|
Telefonica Brasil SA ADR
NYSE:VIV
|
0.081x |
|
Roku Inc
NASDAQ:ROKU
|
0.101x |
|
China Securities Co Ltd
SHG:601066
|
0.237x |
|
Raiffeisen Bank International AG
VI:RBI
|
-0.142x |
|
NiSource Inc
NYSE:NI
|
0.057x |
|
PTT Exploration and Production Public Company Limited
BK:PTTEP
|
0.085x |
|
US Foods Holding Corp
NYSE:USFD
|
0.068x |
Annual Cash Flow Conversion Efficiency for Roivant Sciences Ltd (2019–2025)
The table below shows the annual cash flow conversion efficiency of Roivant Sciences Ltd from 2019 to 2025. Review ROIV FCF to total liabilities ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | $5.19 Billion | $-839.45 Million | -0.162x | -36.37% |
| 2024-03-31 | $6.45 Billion | $-765.27 Million | -0.119x | +77.38% |
| 2023-03-31 | $1.61 Billion | $-843.39 Million | -0.525x | -59.58% |
| 2022-03-31 | $2.06 Billion | $-677.73 Million | -0.329x | -28.73% |
| 2021-03-31 | $2.16 Billion | $-552.14 Million | -0.255x | +29.31% |
| 2020-03-31 | $2.11 Billion | $-761.83 Million | -0.361x | +66.94% |
| 2019-03-31 | $937.30 Million | $-1.02 Billion | -1.093x | -- |
About Roivant Sciences Ltd
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody that targets the neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease… Read more